The opportunity is to move that infrastructure from pure affordability toward controlled portions, fortified staples, protein-rich snacks, shelf-stable dairy alternatives and waste-reducing packs
R&D and Innovation: Pharmaceutical companies are continuing to invest in the development and innovation of GLP-1RA drugs that should lead to increased efficacy, further use cases and reduced side effects
However, GLP-1RAs are also associated with substantial adverse events and out-of-pocket costs, which could contribute to their discontinuation
Commonly reported effects in studies include nausea, diarrhoea, vomiting and constipation
The discussion here is limited to FDA-approved uses in adults
Journal of Diabetes Investigation